For more than three decades, disease modification has remained one of the central ambitions of Parkinson’s disease research.

Researchers have identified numerous pathological abnormalities, cellular disturbances, and genetically implicated pathways associated with the disease. These include α-synuclein aggregation, altered lysosomal and glucocerebrosidase function, mitochondrial impairment, disrupted proteostasis, oxidative stress, neuroinflammatory responses, and pathways implicated by inherited forms of parkinsonism.

These discoveries substantially expanded how Parkinson’s disease is understood.

They also generated optimism that clinical progression might eventually be slowed—or that the emergence of clinically defined disease might be delayed in carefully selected at-risk populations.

Yet no therapy has been conclusively demonstrated and adopted as a disease-modifying treatment for Parkinson’s disease.

That statement requires careful interpretation.

Several treatments substantially improve symptoms. Deep-brain stimulation can improve selected levodopa-responsive motor symptoms and complications in appropriately selected patients. Early cell-replacement programmes have produced imaging findings consistent with graft survival and dopaminergic activity, although those findings are indirect and definitive efficacy, functional integration, and long-term durability remain under evaluation.

None of these achievements, by itself, proves durable slowing of the broader neurodegenerative process.

The limited success of disease-modification programmes should therefore not be viewed simply as a succession of failed clinical trials.

It reflects the difficulty of translating biological knowledge into an intervention that:

The question facing Parkinson’s disease research has therefore begun to change.

For many years, investigators asked:

“Can we discover a therapy that slows Parkinson’s disease?”

Increasingly, they are asking:

“What would convincing disease modification actually look like?”

Disease modification has often been discussed as though one broadly effective treatment might slow progression across most clinically diagnosed patients.

That possibility remains open.

Biological heterogeneity does not exclude a treatment acting on an important pathway shared across large numbers of patients.

At the same time, researchers are examining whether some interventions may work best in populations selected according to particular biological characteristics.

Patients satisfying the same clinical diagnostic criteria can differ in genotype, α-synuclein seeding status, clinical phenotype, progression rate, and measurable patterns of nervous-system dysfunction.

Some carry variants linked to glucocerebrosidase biology, mitochondrial quality control, vesicular trafficking, or other biological pathways. Others demonstrate α-synuclein seeding activity—a feature shared across neuronal synucleinopathies rather than one specific to the clinical syndrome of Parkinson’s disease.

These findings reveal biological variation.

They do not yet identify, with sufficient reliability, the dominant process driving progression within an individual patient.

Biological heterogeneity may nevertheless contribute to difficulty detecting treatment effects across broadly defined populations. It is only one possible explanation.

A programme may also fail because the selected target is insufficiently important, the therapy modifies the wrong molecular species, central exposure is inadequate, treatment begins after extensive downstream pathology has developed, toxicity limits dosing, treatment duration is insufficient, or the trial cannot detect the relevant effect.

Many negative trials do not reveal which explanation was decisive.

Meanwhile, Parkinson’s disease research has acquired tools that were largely unavailable a decade ago.

Molecular assays can identify selected disease-associated biological states.

Genetic testing can identify populations linked to defined pathways.

Longitudinal cohorts can estimate progression probabilities.

Digital technologies can repeatedly measure real-world function.

Clinical trials can increasingly enrich or stratify participants according to genetic and molecular characteristics.

These tools do not prove that disease modification is achievable.

They allow more precise questions:

Some future developments appear increasingly likely.

Others remain plausible but unproven.

Still others will require substantial scientific advances.

The original idea was deceptively straightforward.

If a biological process contributes to progressive nervous-system dysfunction or degeneration, modifying that process might durably slow a defined component of Parkinson’s disease progression.

Whether researchers focused on α-synuclein, mitochondria, lysosomes, oxidative injury, inflammation, calcium handling, glucocerebrosidase biology, or neurotrophic signalling, the therapeutic sequence was similar:

Identify an important biological process.

Modify it safely.

Preserve vulnerable neural structure or function.

Produce durable slowing of clinically meaningful progression.

Every step contains assumptions.

Finding an abnormality does not establish that it is the most important therapeutic target.

A process may initiate disease.

It may amplify progression.

It may arise secondarily after nervous-system dysfunction is already established.

It may represent a compensatory response attempting to limit injury.

The target must therefore be sufficiently causal or rate-limiting at the stage being treated.

It must remain modifiable.

And it must be targetable with an acceptable balance between potential benefit and harm.

A biologically important target may still be clinically unusable if meaningful modification requires excessive systemic toxicity, invasive administration, chronic immunosuppression, or exposure that cannot be sustained over years.

Parkinson-related biology probably changes over time.

A process important near initiation may become less influential after interacting abnormalities involving protein handling, mitochondrial function, lysosomes, inflammation, axons, synapses, glia, and neural networks have developed.

Some downstream processes may eventually become partly self-sustaining.

That is a plausible model—not a proven explanation for previous negative trials.

It nevertheless suggests that different interventions may have different optimal windows.

A treatment directed at a relevant process could still be ineffective if administered after that process has ceased to be a major determinant of progression.

Earlier treatment would not automatically solve the problem.

The correct biological process must still be identified, modified safely, and altered sufficiently to influence a clinically meaningful outcome.

Target engagement is often described as though it were a single event.

In reality, it can involve progressively stronger levels of evidence:

Even completion of this chain does not guarantee alteration of the clinical trajectory.

The targeted process may not be sufficiently important.

The pharmacodynamic effect may be too small or too transient.

Parallel mechanisms may continue to sustain progression.

Target engagement therefore shows that a therapy has influenced its intended pathway.

It does not, by itself, establish disease modification.

Parkinson’s disease is clinically defined and shows substantial biological heterogeneity.

Patients can differ in genotype, α-synuclein-associated biology, phenotype, progression, and pathology.

Different pathways may contribute to different degrees across patients.

They may ultimately differ in response to mechanism-specific therapy, although prospective evidence that current classifications predict differential treatment response remains limited.

This does not mean every person will require a unique intervention.

A therapy directed at an important shared pathway might benefit many patients.

Other treatments may prove useful mainly in genetically or molecularly enriched populations.

The future could include both approaches.

This possibility has helped motivate new biological research frameworks.

The SynNeurGe research diagnostic criteria characterise Parkinson’s disease through three biological dimensions:

The framework was proposed as a research biological classification rather than an established treatment-selection system. It may already support more explicit biological cohort description. Whether it improves prognostic calibration, trial efficiency, treatment selection, or patient outcomes remains to be demonstrated.

It defines disease through pathological neuronal α-synuclein as its S biological anchor, incorporates dopaminergic-system dysfunction as its D anchor, and stages increasing clinical and functional impairment across a proposed disease continuum. It does not encompass every form of clinically diagnosed Parkinson’s disease or parkinsonism.

Neither SynNeurGe nor NSD-ISS replaces clinical diagnosis.

Clinical diagnosis identifies the current syndrome, guides differential diagnosis, evaluates disability, and informs present management.

Biological classification identifies selected molecular or physiological features.

Neither alone fully captures prognosis, treatment requirements, or the patient’s current clinical condition.

The frameworks may initially support more internally coherent research populations.

That potential benefit carries trade-offs.

Narrower eligibility may reduce recruitment feasibility, demographic diversity, and generalisability. It may also exclude clinically important patients who lack the chosen biological marker.

Predicting treatment response remains a substantially higher bar than improving biological description.

Future trials may move away from assuming that there is one universal period during which Parkinson’s disease can be modified.

A treatment directed against a particular α-synuclein species might require intervention before that process becomes widespread or ceases to be rate-limiting.

The relevant therapeutic pool might be intracellular or extracellular, soluble or fibrillar, oligomeric or strain-like. These overlapping categories should not be assumed to be biologically interchangeable.

A glucocerebrosidase-directed intervention may initially be tested in people carrying selected GBA1 variants.

Even within that group, variant severity, penetrance, ancestry, phenotype, and disease course differ.

A therapy intended to preserve dopaminergic terminals requires sufficient remaining neural substrate.

An intervention aimed at cognition or autonomic dysfunction may require a different population, disease stage, and outcome measure.

These remain hypotheses.

For most therapies, the optimal biological state, molecular target, treatment population, and timing remain unknown.

Disease modification is not one indivisible endpoint.

It might mean:

These claims are not interchangeable.

A therapy shown to slow one motor endpoint should not automatically be described as modifying cognition, autonomic disease, or the whole multisystem disorder.

Every claim should specify:

A validated surrogate endpoint must show that a treatment-induced biomarker change reliably predicts a treatment-induced change in a clinically meaningful outcome.

Correlation with diagnosis, severity, prognosis, or natural history is insufficient.

No biomarker is currently established as a validated surrogate endpoint capable of replacing clinically meaningful outcomes in Parkinson’s disease trials.

The biological idea of the next decade is therefore more demanding than the original one:

The belief that Parkinson’s disease might eventually be modified did not arise from a single discovery.

It developed as several lines of evidence appeared to converge.

Human genetics identified biological pathways capable of causing or predisposing to parkinsonism.

Neuropathology revealed recurring molecular abnormalities.

Experimental models demonstrated that manipulating selected pathways could influence dopaminergic injury or behaviour.

Observational studies generated therapeutic hypotheses.

Molecular biomarkers began identifying disease-associated biology in living participants.

Longitudinal cohorts improved estimates of progression.

Trial methodology became more sophisticated.

These forms of evidence answered different questions.

Some established association.

Some supported causality in selected inherited disorders.

Some demonstrated mechanistic plausibility.

None, by itself, proved that modifying the pathway would slow Parkinson’s disease in patients.

Pathogenic variants and multiplications involving SNCA showed that altered α-synuclein biology can directly cause familial Parkinson’s disease.

Variants involving LRRK2, VPS35, PRKN, PINK1, PARK7/DJ-1, ATP13A2, and other genes implicated mitochondrial quality control, lysosomal function, vesicular trafficking, autophagy, protein homeostasis, and cellular stress responses.

These genes are not biologically or genetically equivalent.

SNCA, LRRK2, and VPS35 are generally associated with dominant inheritance, with penetrance varying considerably between variants.

PRKN, PINK1, PARK7, and several other forms usually require pathogenic variants in both alleles.

A single heterozygous variant in a recessive gene does not automatically establish causal parkinsonism.

GBA1 also requires careful interpretation.

Some biallelic variants cause Gaucher disease, while heterozygous and biallelic states can confer Parkinson’s disease susceptibility with variant-dependent effects.

Risk, penetrance, age at onset, phenotype, cognitive burden, and progression vary by variant and population.

Genetics therefore provides strong biological anchoring for selected pathways.

It does not prove that the implicated pathway remains rate-limiting after diagnosis or that modifying it will slow progression.

Lewy bodies and Lewy neurites are characteristic pathological findings in many cases of Parkinson’s disease.

The discovery of α-synuclein as a major constituent, together with causal SNCA variants, strengthened the hypothesis that altered protein folding and aggregation contribute to disease biology.

Pathology alone does not establish which molecular species should be targeted.

Soluble oligomers, fibrils, mature inclusions, intracellular species, extracellular species, and conformational assemblies may not have equivalent biological effects.

Inclusion formation might contribute to toxicity.

It might also sequester more toxic soluble species in some contexts.

The therapeutically decisive form remains uncertain.

Toxin models based on MPTP and 6-hydroxydopamine demonstrated that selective dopaminergic injury can produce parkinsonian motor abnormalities.

MPTP is metabolised to MPP+, which enters dopaminergic neurons largely through the dopamine transporter and inhibits mitochondrial complex I.

Other models based on α-synuclein overexpression, seeded aggregation, or genetic manipulation reproduce selected molecular or pathological features.

Interventions have preserved dopaminergic neurons, reduced aggregation, or improved behaviour in many of these systems.

No current model reproduces the full slowly progressive, age-associated, multisystem disorder observed in humans.

Treatment is frequently initiated before or near disease induction, sometimes at doses or through routes that may not be clinically feasible.

Preclinical studies may also be affected by publication bias, incomplete blinding, methodological variability, and endpoints that do not translate directly to patient function.

Experimental success demonstrates plausibility—not clinical efficacy.

Associations have been reported between Parkinson’s disease and factors including serum urate, caffeine consumption, smoking, physical activity, diabetes, inflammatory states, and several medication classes.

The strength, direction, and reproducibility of these associations vary.

Confounding, reverse causation, survivor bias, and changes in behaviour during the prodromal phase can create relationships that do not represent modifiable causes.

Smoking should never be interpreted as a preventive recommendation.

Approved medicines also have established safety for their licensed indications, doses, and populations—not automatically for long-term use in Parkinson’s disease.

Observational evidence can generate hypotheses.

It cannot establish that changing an associated exposure will alter progression.

α-Synuclein seed-amplification assays detect seeding-competent misfolded α-synuclein rather than simply measuring total protein concentration.

They show high overall positivity in many clinically diagnosed Parkinson’s disease cohorts and can detect seeding activity in selected at-risk individuals before conventional motor diagnosis.

Positivity is not synonymous with the clinical syndrome of Parkinson’s disease. It occurs across neuronal synucleinopathies.

SAA-negative results also occur in selected clinically diagnosed populations, including portions of some LRRK2-associated and preserved-olfaction groups.

A positive result does not reliably establish:

Quantitative kinetic measures have shown emerging diagnostic and prognostic associations, but reliable individual prediction and treatment-response monitoring remain insufficiently validated. Kinetic results also remain platform-, protocol-, matrix-, and laboratory-dependent, limiting direct comparison across studies.

Evidence is currently stronger for biological classification than for therapeutic monitoring.

A diagnostic biomarker supports the presence of a biological state.

A prognostic biomarker estimates future course.

A target-engagement biomarker demonstrates interaction with the intended pathway.

A treatment-response biomarker shows biological change associated with treatment.

A surrogate endpoint must reliably predict treatment-induced clinical benefit.

No current marker performs all these functions.

Dopaminergic imaging demonstrates presynaptic nigrostriatal dysfunction but does not establish its cause or measure the entire multisystem disease.

Neurofilament light may reflect neuroaxonal injury but is not Parkinson’s-specific.

Inflammatory and multi-omic markers may be influenced by age, medication, renal function, systemic illness, laboratory methods, and ancestry representation.

Multimarker panels may improve performance.

They may also increase cost, complexity, missingness, and false-discovery risk.

Their added value over simpler approaches must be demonstrated.

Deeply phenotyped cohorts combine clinical assessments, genetics, imaging, biospecimens, digital measures, and repeated follow-up.

They allow investigators to estimate:

These studies estimate probabilities, not certainties.

Genotype is fixed, but its biological and clinical expression may vary with age, environment, and context.

Clinical and data-driven clusters may change with disease stage or with the variables included in the analysis.

A prognostic subgroup is not necessarily mechanistic.

Neither automatically predicts treatment response.

Modern trials increasingly incorporate:

Each method introduces trade-offs.

Enrichment can increase statistical efficiency while reducing generalisability.

Delayed-start and withdrawal studies may remain confounded by persistent symptomatic effects or incomplete washout.

Time-to-event outcomes can reflect physician decisions and healthcare systems as well as biology.

Adaptive trials require strict control of multiplicity and operational bias.

Composite outcomes may be difficult to interpret when their components move in different directions.

Parkinson’s disease progression is also nonlinear and domain-specific. Medication changes, intercurrent illness, practice effects, floor and ceiling effects, and differential dropout can distort estimated trajectories.

Long trials are particularly vulnerable to informative missingness: participants who deteriorate, experience adverse effects, or perceive little benefit may discontinue unevenly between groups.

Better methodology cannot rescue a weak target or an intervention that fails to modify it adequately.

It can improve the chance that a genuine effect will be recognised.

Taken together, genetics, pathology, models, biomarkers, cohorts, and trial methods made biologically informed disease modification more testable.

They did not make it proven.

Every disease-modification programme must ultimately answer one question:

Does modifying the proposed biology produce durable, clinically meaningful slowing of Parkinson’s disease?

Collectively, trial results have been informative, although many negative studies have not resolved precisely why the tested strategy failed.

Mitochondrial dysfunction illustrates the problem.

Mitochondrial abnormalities and the MPTP model provided strong rationale for testing energy-support and antioxidant strategies.

The phase III QE3 study of high-dose coenzyme Q10 was stopped for futility.

The NET-PD LS-1 trial of creatine was also terminated for futility and found no clinical benefit.

These trials do not establish that mitochondrial dysfunction is irrelevant.

They establish that the tested interventions, doses, populations, durations, and outcome measures did not demonstrate clinically meaningful slowing.

The trials did not determine whether failure reflected inadequate biological effect, poor target engagement, timing, pathway redundancy, or an insufficiently important target.

The 2026 LUMA results provided a particularly relevant example.

BIIB122 was developed as an oral LRRK2 inhibitor and tested in early Parkinson’s disease.

According to the sponsors’ May 2026 report, LUMA did not meet its primary or secondary clinical endpoints. The sponsors also reported expected blood and cerebrospinal-fluid exposure, greater than 90% inhibition of peripheral LRRK2 phosphorylated at serine 935, and an approximately 30% reduction in cerebrospinal-fluid phosphorylated Rab10 in a substudy.

Despite these pharmacological and pharmacodynamic findings, detectable clinical slowing was not demonstrated. Development in idiopathic Parkinson’s disease was discontinued, while the genetically enriched BEACON study in pathogenic LRRK2-variant carriers continued.

LUMA does not prove that LRRK2 is therapeutically irrelevant.

It tested one inhibitor, dose, population, disease stage, duration, and endpoint structure.

It does demonstrate that strong biological rationale and measurable pathway engagement are insufficient evidence of clinical disease modification.

Neurotrophic-factor programmes illustrate the difficulty of delivering large biological therapies to relevant brain regions.

GDNF and neurturin produced encouraging preclinical findings.

The CERE-120 programme used viral-vector delivery of neurturin but failed its primary efficacy endpoint.

Delivery, anatomical coverage, disease stage, and responsiveness of the remaining neural substrate were plausible limitations.

The trial did not establish which factor was decisive.

It demonstrated that the tested strategy did not provide convincing clinical benefit under the study conditions.

α-Synuclein immunotherapy was supported by human genetics, Lewy pathology, and experimental evidence.

The phase II PASADENA trial of prasinezumab did not meet its primary clinical endpoint and showed no meaningful effect on global or dopamine-transporter imaging measures compared with placebo.

The phase IIb PADOVA study also missed its primary endpoint.

Roche judged the totality of exploratory, subgroup, and extension findings sufficient to proceed to the phase III PARAISO trial. That development decision does not establish efficacy.

Prasinezumab remains unproven after two missed phase II primary endpoints, while phase III testing continues to evaluate the unresolved hypothesis.

Possible explanations—including the molecular species targeted, treatment timing, heterogeneity, central engagement, or endpoint sensitivity—remain post-hoc hypotheses rather than conclusions established by the trials.

Higher serum urate was associated with slower progression in observational cohorts, motivating the SURE-PD3 trial of inosine.

Inosine increased serum urate but did not produce convincing slowing.

Similarly, epidemiological associations involving calcium-channel blockers led to the STEADY-PD III isradipine trial, which did not establish disease modification.

These programmes illustrate that an associated biological variable may be a marker rather than a causal mediator.

It may also be causally relevant but not therapeutically reversible in the manner tested.

Changing the variable does not necessarily change the disease.

GBA1 biology provides strong genetic rationale for therapies intended to enhance glucocerebrosidase or lysosomal function.

Early ambroxol studies examined safety, central exposure, and pharmacodynamic effects. Randomised studies are evaluating whether those findings translate into clinical benefit.

Target engagement or central exposure can support a therapeutic mechanism.

They do not establish that glucocerebrosidase enhancement slows Parkinson’s disease.

GLP-1 receptor agonists provide another caution.

The published Exenatide-PD3 report found no evidence supporting exenatide as a disease-modifying treatment. On 22 June 2026, The Lancet issued an Expression of Concern concerning that publication; until the editorial issue is resolved, the report should be interpreted with that qualification.

A phase II study of lixisenatide reported less worsening in its prespecified motor outcome over 12 months.

That was an encouraging phase II motor signal—not proof of neuronal protection or established disease modification.

The study was relatively short, gastrointestinal adverse effects were common, and replication remains necessary.

Agents grouped within one pharmacological class may differ in receptor pharmacology, central exposure, dosing, tolerability, and off-target effects.

Class membership does not guarantee shared efficacy.

Genetics, SAA, imaging, and computational approaches can identify biological differences between participants.

That represents progress.

It does not establish that the identified categories should determine treatment.

Some clinical and data-driven subgroups show prognostic associations in selected cohorts, but reproducibility and longitudinal stability remain inconsistent.

Body-first and brain-first models remain debated mechanistic frameworks rather than validated treatment-selection systems.

No biomarker is currently established as a surrogate endpoint capable of replacing clinically meaningful outcomes in Parkinson’s disease trials.

No biomarker-defined strategy has yet established reproducible mechanism-matched disease-modifying benefit.

The maturity of the field is uneven:

The field is increasingly capable of enriching and biologically characterising trial populations.

It is not yet able to identify reliably which person will benefit from which therapy.

Most trials did not fail because Parkinson's disease is untreatable.

They showed that

the biology,

the timing,

the patient,

or the therapeutic strategy

was probably not yet right.

One central obstacle is not the shortage of plausible targets.

It is determining which targets are therapeutically important and translating their modification into benefit that matters to patients.

Biological classification can improve cohort description, enrich trials, and test mechanism-specific hypotheses.

Its ability to improve routine clinical decisions remains unproven.

Clinical diagnosis and biological classification answer different questions.

Clinical diagnosis identifies the current syndrome and guides management.

Biological classification describes selected molecular or physiological features.

Neither replaces the other.

Biologically narrower cohorts may improve internal consistency.

They may also reduce recruitment feasibility, population diversity, and generalisability, while excluding clinically important patients who lack the selected marker.

Precision medicine should therefore be judged by whether biomarker-guided decisions improve outcomes—not by the sophistication of the classification itself.

A broadly useful therapy targeting a shared pathway remains possible.

Subgroup-specific and broad strategies may coexist.

Future delay-of-conversion trials may recruit people using combinations of:

These states are not interchangeable.

Isolated RBD carries a high risk of a future synucleinopathy-spectrum disorder in specialist cohorts but does not predict Parkinson’s disease specifically.

Genetic penetrance may be incomplete and age-dependent.

SAA positivity identifies seeding activity without reliably predicting phenotype or timing.

Abnormal dopaminergic imaging indicates established presynaptic nigrostriatal dysfunction rather than necessarily representing the earliest disease stage.

Combining correlated markers does not automatically improve prediction. Risk models require prospective calibration and external validation across diverse populations.

Earlier treatment also raises the required safety standard.

The acceptable risk depends on:

Trials are increasingly beginning to enrich or stratify participants according to genetic and biological characteristics.

That is trial design—not routine treatment selection.

A biomarker becomes clinically useful only when using it to choose treatment produces better outcomes than not using it.

Genetic enrichment is currently more mature than many proposed inflammatory, metabolic, mitochondrial, or lysosomal profiles.

SAA is valuable for biological characterisation, but it has not been validated as a predictor of response to an α-synuclein-directed therapy.

If multiple parallel or stage-dependent processes sustain progression, single-target intervention may be insufficient.

Combination treatment is therefore plausible.

It is not established.

Simultaneous multidrug strategies introduce additive toxicity, drug interactions, statistical multiplicity, and difficulty identifying the effective component.

Sequential or stage-specific combinations may be more feasible.

Their value must be demonstrated empirically.

A disease-modifying treatment aims to alter ongoing progression.

A restorative treatment aims to recover function already lost.

Cell replacement may provide local dopaminergic reinnervation or improve selected circuit function without reconstructing the normal nigrostriatal pathway.

Neuromodulation can improve symptoms by changing network activity.

Neither is automatically disease-modifying.

Conversely, a therapy that genuinely slows progression may produce little immediate symptomatic improvement.

Future care may combine symptomatic, restorative, and disease-slowing therapies while maintaining clear evidentiary distinctions among them.

Biomarkers can support development.

They cannot replace the question of whether patients preserve meaningful function.

Depending on the mechanism and population, relevant outcomes may include:

A therapy need not improve every domain.

Its claim must be defined domain by domain.

Disease modification requires:

Biomarker-defined treatments may require companion diagnostics.

Those diagnostics need independent analytical and clinical validation.

Regulators may need to evaluate:

Narrow indications may make post-marketing evidence more—not less—important.

Implementation may require genomic testing, lumbar puncture, specialised imaging, digital infrastructure, advanced laboratories, and specialist interpretation.

Availability, reimbursement, ancestry representation, affordability, and geographical access will influence who benefits.

A scientifically effective therapy that cannot be delivered equitably will have limited population impact.

These categories do not imply that subgroup-specific treatment is intrinsically more likely to succeed than a broadly effective therapy. Current evidence does not permit that ranking confidently.

It may not arrive as one uniform breakthrough.

It may begin with better trials before it transforms clinical care.

It may involve a broadly applicable treatment, a subgroup-specific therapy, or both.

One biomarker may identify eligibility.

Another may demonstrate target engagement.

Clinical outcomes will still be required to establish meaningful benefit.

The first successful therapy may slow one defined aspect of progression modestly but reproducibly, with a clinically important effect size, appropriate confirmation, and acceptable benefit–risk balance.

It may work only during a particular disease stage.

Its benefit may become visible over years rather than weeks.

That would still represent genuine progress.

The field should avoid two opposite errors.

A modest but durable clinical effect should not be dismissed because it is not a cure.

A biomarker shift, exploratory subgroup result, or pharmacodynamic signal should not be called disease modification without reproducible clinical evidence.

The next decade may determine whether the biological and methodological framework now being built can produce the first clinically meaningful disease-modifying benefit in Parkinson’s disease.

That—not the number of biomarkers, algorithms, or candidate pathways discovered—will be the standard by which progress should ultimately be judged.

—

Think Beyond the Headline.

Heart disease remains the leading cause of death worldwide. Yet one question has shaped cardiovascular medicine for more than half a century:

Did cholesterol truly cause atherosclerosis?

In the next issue of The Clinical Logic, we'll trace the origins of the cholesterol hypothesis—from early pathological observations and landmark epidemiological studies to the evidence that transformed cholesterol into the dominant explanation for cardiovascular disease.

We'll examine how the idea emerged, why it became so influential, and what the science actually showed.